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ABSTRACT The vitamin K-dependent matrix Gla protein
(MGP) is synthesized in a wide variety of tissues such as lung,
heart, kidney, cartilage, and bone. Expression of the MGP
gene is regulated by various growth factors, steroid hormones,
and the vitamin A metabolite retinoic acid (RA). In this
report, we present evidence that RA down-regulatesMGP gene
expression in different rat and human cell lines via endoge-
nous retinoid receptors [RA receptor (RAR) and retinoid X
receptor (RXR)]. Repression of the human MGP (hMGP)
gene is specifically mediated by ligand-activated RAR and
RXR. Deletion analysis led to the identification of a novel
negative response element (NRE) within the hMGP promoter.
DNA binding studies performed with bacterially expressed
RARyRXR reveal the formation of a specific heterodimery
NRE complex. Furthermore, electrophoretic mobility-shift
assays performed with proteins from RA-treated cells show
that endogenous RARyRXR binds to the NRE. We demon-
strate that the NRE contains a CCAAT box and that both
RARyRXR and CCAAT-binding proteins such as cyEBPb
recognize this common regulatory sequence in the hMGP
promoter. Our results indicate that RA-mediated repression
of the hMGP gene is due to binding of liganded RARyRXR to
a novel negative RA response element.
Matrix Gla protein (MGP) is a 10-kDa, vitamin K-dependent
protein that serves as a substrate for the enzyme g-carboxylase,
which converts glutamic acid to g-carboxyl-glutamic acid
(Gla). MGP expression has been detected in all vertebrate
tissues, with the highest levels in cartilage, kidney, lung and
heart (1). MGP is a secreted protein and accumulates to
significant levels in the extracellular matrix of bone, cartilage,
and calcified cartilage (2–4). Following the original isolation
from bone (2, 3), MGP has been independently identified by
differential cDNA screening as a gene that is overexpressed in
primary human breast cancer cells (5), in prostate epithelial
cells which undergo apoptosis (6), and in differentiated vas-
cular smooth muscle cells (7). Although the exact function of
MGP is presently unknown, there is evidence to suggest that
the protein may play a role in cell growth and tumorigenesis.
Interestingly, MGP gene expression is regulated by several
growth factors and hormones. Especially, retinoic acid (RA)
has been implicated in modulating MGP gene expression.
Retinoids play an important role in development, cellular
proliferation, and differentiation and are well-known inhibi-
tors of cell growth. Furthermore, retinoids can be effective
therapeutic agents in treating certain human cancers (8). RA
exerts biological effects by acting through at least two distinct
classes of intracellular proteins including the RA receptors
(RARs) and the retinoid X receptors (RXRs), both of which
are members of the nuclear receptor superfamily. While both
the RARs and RXRs are effective activators of some genes,
RA is also known to repress gene expression. The inhibitory
effects of RA on gene transcription can be exerted through
various mechanisms such as competition between receptors
and other transcription factors for overlapping binding sites (9,
10) or by competition for limiting cofactors (11, 12).
To further extend our understanding of RARyRXR-
mediated repression, we examined the effect of RA on the
regulation of human (hMGP) gene expression. In this report,
we show that RA is able to repress endogenous MGP gene
expression in different cell lines. To identify cis-regulatory
promoter elements that mediate RA-dependent repression we
cloned and characterized the 59 f lanking region of the hMGP
gene. Deletion analysis of the hMGP promoter identified a
37-bp region that is both necessary and sufficient to confer
repression by RA. Electrophoretic mobility-shift assays
(EMSAs) show that both RARyRXR, expressed endoge-
nously in NRK52E cells or recombinant receptors, bind to this
novel negative response element (NRE). This NRE shows no
sequence homology to other known RAR response elements,
but contains a CCAAT box. Both RARyRXR and the CAAT-
binding protein cyEBPb recognize the NRE, and cyEBPb
competes with RARyRXR for binding to the NRE. Conse-
quently, overexpression of cyEBPb abrogates RA-mediated
repression of the hMGP promoter. Finally, transient transfec-
tion analysis of RAR deletion mutants reveals that the DNA
binding domain (DBD) and the activation domain (AF-2) of
RAR are required for repression.
MATERIALS AND METHODS
Cell Culture and Transfection. NRK52E cells were cultured
in Ham’s F-12 medium. MCF-7 cells were cultured in Earl’s
modified Eagle’s medium (EMEM). Both media were supple-
mented with 10% fetal calf serum. Transient transfection
assays were carried out using the standard calcium phosphate
coprecipitation technique (13) as described in ref. 14.
NRK52E cells were exposed to the precipitate for 4 hr
following a 2-min 10% dimethyl sulfoxide shock. Luciferase
(LUC) activity was assayed as recommended by the manufac-
turer (Promega) in the Luminometer ML 3000 (Dynatech).
Relative light units were normalized to b-galactosidase activity
(15) and protein concentration using the Bradford dye assay
(Bio-Rad). All experiments were repeated at least five times.
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Reporter Plasmids. The LUC reporter plasmids bRE2-
TKLUC and (SPP)x2-TKLUC were described previously (15).
The hMGPLUC reporter plasmid -3600LUCwas generated by
inserting a 3.6-kb hMGP promoter fragment at the KpnI–BglII
restriction sites of pGL2LUC (Promega). The constructs
-560LUC, -300LUC, -168LUC, -132LUC, and -560 D 168–
132LUC were generated using PCR amplification followed by
inserting the PCR products at the BglII–HindIII restriction
sites of pGL2LUC.
Expression Vectors. The eukaryotic expression plasmids
CMX-hVDR, CMX-hRARa, CMX-hRXRa, CMX-
RARa403*, CMX-RARa-DBD, CMX-RARa DDBD, CMX-
RARa-N, CMX-RARa-C, and MSV-cyEBPb were described
previously (14–16).
DNA Binding Studies.Whole cell extracts from NRK52E cells
were prepared as recommended (17). The glutathione S-
transferase (GST) fusion proteins were expressed according to
ref. 18. The purified GST fusion proteins or 2 ml of whole cell
extracts were mixed with sample buffer resulting in a final
concentration of 10 mM Tris (pH 8.0), 40 mM KCl, 0.05%
Nonidet P-40, 6% (volyvol) glycerol, 1 mM DTT, 1 mg poly(dI-
dC). Approximately 0.5 ng of the 32P-labeled oligonucleotide
probe was added to the reaction mixture and incubated on ice for
30 min. Subsequently, the samples were loaded on 5% nonde-
naturing polyacrylamide gels in 0.53TBE running buffer at 48C.
After electrophoresis, gels were dried and subjected to autora-
diography at2708C. The following oligonucleotides were used in
gel retardation assays: NRE (59-TGTTTGGGAAAAGTTC-
CAATGCTAGTTAAGTGCCAAC-39), MT1 (59-AGTTC-
CAATGCTAGTTAAGTGCCAAC-39), MT2 (59-AGTTC-
CAATGCTAGTTA-39), DR2 (59-AGCTTCAGGTCAGGAG-
GTCAGAG-39), and DR5 (59-AGCTTCAGGTCACCA-
GGAGGTCAGAG-39). To determine the composition of vari-
ous DNAyprotein complexes the following antibodies were in-
cluded in the reactionmixtures: a-RAR and a-RXR (Santa Cruz
Biotechnology), a-Flag (Kodak), and a-cyEBPb (generous gift
from K.-H. Klempnauer, MPI fu¨r Immunobiologie, Freiburg,
Germany).
Northern Blots. Total RNA was prepared and subjected to
Northern blot analysis using standard procedures (19). Hy-
bridizations were performed by using hMGP, rat MGP, and
mouse b-actin cDNA probes in a buffer containing 50%
formamide at 428C for 16 hr. The final washes were done in
0.1 3 SSC at 608C. The Northern blots were quantified by
densitometry (Molecular Dynamics, Model 300A).
Radioimmunoassays. MCF-7 and NRK52E cells were cul-
tured until they had attained visual confluence. Culture me-
dium was exchanged for fresh medium supplemented with
ethanol vehicle or 1026 M all-trans RA. After 24 hr, condi-
tioned medium was collected from three to five individually
treated dishes, centrifuged to remove any cellular debris, and
aliquots of 0.2 ml were analyzed by radioimmunoassay in
triplicate for MGP protein content as described (20).
RESULTS
RA Inhibits MGP Gene Expression. To evaluate the effects of
RA on the expression of the endogenous MGP gene, the human
breast cancer cell line MCF-7 and the rat kidney cell line
NRK52E were treated for 24 hr with RA, and the levels of MGP
mRNA were determined by Northern blot analysis. As shown in
Fig. 1 A and B, RA decreased MGP mRNA levels in both the
MCF-7 (lane 2) and NRK52E cells (lane 4) to '30% of the
untreated control levels. RA-mediated repression is specific since
RA treatment has no effect on the expression of the b-actin
control gene (Fig. 1A, lanes 2 and 4).RAdecreasedMGPmRNA
levels in the absence of new protein synthesis and as early as 10
hr after treatment (data not shown). To determine whether
repression of MGP mRNA expression correlates with reduced
levels of MGP protein, MCF-7 and NRK52E cells were treated
for 24 hrwithRAand the amounts of secretedMGPproteinwere
determined by radioimmunoassays. In both cell lines, MGP
protein levels are drastically reduced by RA treatment (Fig. 1C,
FIG. 1. Inhibition of MGP gene expression by RA. (A) Cell lines
MCF-7 and NRK52E were grown in the absence or presence of 1026
M all-trans RA. MGP mRNA levels were analyzed by hybridization
with cDNA probes encoding the human (lanes 1 and 2) or the rat MGP
(lanes 3 and 4) gene, respectively. The amount of RNA loaded in each
lane was controlled by hybridization with a mouse b-actin cDNA. (B)
Densitometric quantitation of the MGPmRNA levels shown in A. The
relative ratios ofMGPyb-actin RNA in untreated cells are set as 100%.
(C) RA treatment represses the level of MGP antigen in conditioned
medium of MCF-7 and NRK52E cells. Cells were incubated with
ethanol vehicle (open bars) or 1026 M all-trans RA (hatched bars) for
24 hr. The levels of MGP antigen secreted into the conditioned
medium were assayed by radioimmunoassay. The amount of MGP
antigen secreted by the ethanol-treated control cells is set as 100%.
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lanes 2 and 4). Taken together, these results demonstrate thatRA
is able to repress MGP gene expression in rat and human cells
under physiological conditions.
RA-Mediated Repression of hMGP Promoter Activity. To
investigate the mechanism of repression, we fused a 3600-bp
fragment of the hMGP promoter to the firefly LUC reporter
gene. Transcriptional activity of the hMGP reporter construct
was monitored following transient transfection in NRK52E
cells. As shown in Fig. 2A, activity of the -3600LUC reporter
is significantly repressed in RA-treated cells (Fig. 2A, bar 1).
Cotransfection of either RAR or RXR expression plasmids
results in a even more dramatic RA-dependent repression
(Fig. 2A, bars 2 and 3). Interestingly, the RAR- or RXR-
specific ligands TTNPB and LG100153 also inhibit -3600LUC
FIG. 2. RA induced down-regulation of the hMGP promoter. (A) Reporter plasmids (1.25 mg) -3600LUC, bRE2-TKLUC, and (SPP)x2-TKLUC
were transfected in NRK52E cells. Transcriptional activity was analyzed either by taking advantage of endogenous retinoid receptor activity present
in NRK52E cells (bar 1) or by cotransfection of 125 ng CMX plasmids expressing RAR, RXR, or VDR. Cells were either untreated (open bars)
or treated with 1026 M all-trans RA (hatched bars), 1027 M TTNPB (shaded bars), 1027 M LG100153 (cross-hatched bars), or with 1026 M D3
(solid bars). (B) Indicated reporter plasmids (1.25 mg), together with 125 ng of CMX-RAR and CMX-RXR expression plasmids, were cotransfected
into NRK52E cells. Transcriptional repression is presented as ‘‘fold repression.’’ (C) Nucleotide sequence of the first 209 bp of the hMGP 59 f lanking
region. The NRE located from position 2168 to 2132 bp is marked by the open rectangle. The TATA box is underlined. Arrow indicates the
transcription initiation site. The ATG start codon of the hMGP coding region is underlined and shown in italics.
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reporter activity '10-fold (Fig. 2A, bars 2 and 3). Cotrans-
fection of both RAR and RXR expression plasmids further
enhances the ligand-mediated repression (Fig. 2A, bar 4). In
contrast, the control plasmid bRE2-TKLUC, which contains
a known RA response element is activated by RA, indicating
that RA-mediated repression is specific for the hMGP pro-
moter (Fig. 2A, bar 6). In addition, cotransfected vitamin D
receptor (VDR) fails to repress the hMGP promoter in
NRK52E cells (Fig. 2A, bar 5), whereas the control plasmid
(SSP)x2-TKLUC, which contains a well-known VDR element
(15) is activated by D3 (Fig. 2A, bar 7). Taken together, these
data demonstrate that RA-induced repression of hMGP pro-
moter activity is specifically mediated by hormone-activated
RARyRXR, whereas VDR and several other nuclear recep-
tors fail to repress hMGP promoter activity.
To further delineate the sequences responsible for repression
of hMGP promoter activity, we generated a series of promoter
deletion mutants and tested these constructs in transient trans-
fection assays in NRK52E cells. Subsequent deletions of 59
flanking sequences up to the position 2168 bp do not alter
repression by RAR and RXR significantly (Fig. 2B, bars 1–4).
However, a reporter construct containing only the promoter
region up to position 2132 bp is no longer down-regulated by
ligandedRARyRXR (Fig. 2B, bar 5). Importantly, the activity of
the internal mutant -560D168–132 LUC is also not repressed by
ligand-activated RARyRXR (Fig. 2B, bar 6). These results
demonstrate that the DNA sequences located between2168 and
2132 bp contain a NRE that is necessary and sufficient to confer
RA-mediated repression (Fig. 2C).
Both the AF-2 and the DBD of RAR Are Necessary for
Repression. The above experiments demonstrate that the
hMGP promoter is efficiently repressed by RARyRXR in a
ligand-dependent manner. To define the domains of RAR
involved in repression, several receptor mutants were analyzed
in cotransfection studies in NRK52E cells for their ability to
repress -560LUC reporter activity. All mutants were expressed
in similar amounts in the tested cells (data not shown). The
C-terminal truncation mutant RAR403* is unable to repress
(Fig. 3, compare bars 2 and 3). Also, deletion of the DBD
results in a complete loss of repression (Fig. 3, bar 4). Further
analysis confirm that RAR mutants, which express either the
C terminus (RAR-C) or the N-terminus (RAR-N), also fail to
repress (Fig. 3, bars 5 and 6). In conclusion, these data suggest
that RAR-mediated repression requires both the DBD and an
intact ligand binding domain of RAR.
RARyRXR Bind to the hMGP Promoter. To investigate the
molecular basis of RA repression, we examined the potential
of RAR and RXR to bind to the NRE in vitro. Therefore, we
performed EMSAs with bacterially expressed GST-RAR and
GST-RXR proteins. GST-RAR forms a specific complex with
an oligonucleotide that includes a single copy of the NRE (Fig.
4A, lane 2). Addition of equal amounts of RXR enhances the
binding of RAR (Fig. 4A, lane 4), whereas RXR alone does
not bind (Fig. 4A, lane 3). The RARyRXR complex is
supershifted by both a-RAR and a-RXR antibodies. Oligo-
nucleotides containing known RARyRXR binding sites (DR5
and DR2) are able to compete for RARyRXR binding (Fig.
4A, lanes 7–10). As expected, the DR5 element competes more
efficiently than the DR2-containing oligonucleotide. Impor-
tantly, binding of RARyRXR is also efficiently competed by
the addition of unlabeled NRE (2168 to2132 bp)-containing
oligonucleotide (Fig. 4A, lane 12). In contrast, the 59-truncated
mutant oligonucleotide MT1 (2157 to 2132 bp) competes
with greatly reduced affinity (Fig. 4B, lanes 4 and 5), whereas
the mutant oligonucleotides MT2 (2154 to2137 bp) is unable
to compete (Fig. 4B, lanes 6 and 7).
To establish that the RARyRXR endogenously expressed in
NRK52E cells binds to the NRE sequence, we performed
additional EMSAs. Proteins present in whole cell extracts from
RA-treated NRK52E cells are able to form the DNAyprotein
complexes I, II, and III (Fig. 4C, lane 2). These complexes are
competed by a 100-fold molar excess of unlabeled NRE-
containing oligonucleotide (Fig. 4C, lane 3). Complex II is
competed by a 100-fold molar excess of unlabeled DR5 oligonu-
cleotide, indicating that RARyRXR is part of complex II (Fig.
4C, lane 4). Finally, we challenged the EMSAs with an a-RXR
antibody. Complex II is specifically supershifted by the a-RXR
antibody showing that RXR is part of this DNAyprotein complex
(Fig. 4C, lane 6). Incubation with an unrelated a-Flag control
antibody has no influence on the mobility of complex II (Fig. 4C,
lane 5). Taken together, these data reveal that retinoid receptors
present in NRK52E cells bind to the NRE element.
The NRE Is a Common Binding Site for RARyRXR and
cyEBPb. The NRE conferring RA repression to the hMGP
promoter does not show any sequence homology to other known
RAR response elements (Fig. 2C). Interestingly, a CCAAT box
can be mapped within the NRE. To investigate the molecular
basis of hormonal repression in more detail, we examined the
ability of the CAAT-binding protein cyEBPb and RARyRXR
heterodimers to bind to theNRE.Accordingly, we performed gel
mobility-shift experiments using bacterially expressed GST-
RAR, GST-RXR, and GST-cyEBPb proteins. RARyRXR het-
erodimers form a retarded DNAyprotein complex C1 (Fig. 5A,
lane 2). Incubation of the NRE oligonucleotide with GST-cy
EBPb alone results in the formation of two DNAyprotein com-
plexes (C2 and C3), which migrate with different mobilities than
the RARyRXRyNRE complex C1 (Fig. 5A, lane 3). Incubation
of the NRE oligonucleotide with equal amounts of both cyEBPb
and RARyRXR fusion proteins results only in the formation of
complexes C2 and C3 (Fig. 5A, lane 4). To establish the compo-
sition of the different DNAyprotein complexes, we challenged
the EMSAs with specific antibodies directed against RXR,
FIG. 3. Functional analysis of RAR mutants. Transcriptional re-
pression of 1.25 mg of the reporter plasmid -560LUC was assayed in
NRK52E cells cotransfected as indicated (1) with 125 ng expression
plasmids coding for either the full-length RAR, RAR403*,
RARDDBD, RAR-N, or RAR-C. Full-length RAR protein is com-
posed of the N-terminal AyB domain (amino acids 1–87), the DBD
(amino acids 88–152), and the C-terminal ligand binding domain
(amino acids 153–462). RA-dependent repression of -560LUC re-
porter activity obtained without cotransfection of RAR expression
plasmids was set as 1.
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cyEBPb, and an unrelated a-Flag control antibody. Complex C1
is specifically supershifted by the RXR antibody (Fig. 5A, lane 9),
whereas complexes C2 and C3 are supershifted by the cyEBPb
antibody (Fig. 5A, lane 8). However, EMSAs containing both
RARyRXR and cyEBPb proteins are supershifted by the
cyEBPb antibody only (Fig. 5A, lane 7). The a-RXR antibody
fails to supershift complexes C2 and C3 (Fig. 5A, lane 6). Hence,
RARyRXR is not present in complexes C2 and C3. Incubation
with an unrelateda-Flag control antibody has no influence on the
mobility of the complexes (Fig. 5A, lane 5). These in vitro binding
studies show that RARyRXR and cyEBPb do not physically
interact on the NRE. Instead, the data suggest that cyEBPb
competes withRARyRXR for binding to a common binding site.
To investigate the effect of cyEBPb on RARyRXR-
mediated repression, we cotransfected RARyRXR and
cyEBPb expression vectors together with the -168LUC re-
porter plasmid into NRK52E cells. As shown in Fig. 5B,
increasing amounts of cyEBPb expression vectors abolishes
RARyRXR-mediated repression (Fig. 5B, compare bar 1 with
bars 2–4). In summary, these data suggest competition be-
tween RARyRXR and CCAAT-binding proteins, such as
cyEBPb, for a common binding site as a mechanism for the
RA-mediated repression of the hMGP promoter.
DISCUSSION
In this manuscript, we demonstrate that RA functions as a
potent inhibitor of MGP gene expression. To assess the
physiological relevance of RA regulation, we examined the
RA-dependent expression level of the endogenous MGP gene
in different cell lines. Importantly, we demonstrate by North-
ern blot analysis and radioimmunoassays that RA is able to
down-regulate MGP gene expression via endogenous recep-
tors present in the cell lines tested. Repression of hMGP gene
transcription is further increased by enhanced expression of
ligand-activated RAR and RXR. Furthermore, our results
show that MGP gene repression is specifically mediated by
RARyRXR, whereas VDR and several other nuclear hor-
mone receptors fail to repress hMGP promoter activity. In this
respect, it is interesting to note that induction of F9 cell
differentiation, as well as inhibition of F9 cell proliferation, is
achieved by saturating concentrations of an RAR-specific
ligand, in the absence of an RXR ligand, whereas ligand-
mediated activation of both RAR and RXR is required to
obtain efficient apoptosis in F9 cells (21). In contrast, repres-
sion of hMGP gene activity can be achieved independently by
ligand-activated RAR or RXR.
To delineate the cis-regulatory sequences that are respon-
sible for RA-mediated repression, we performed functional
analysis with various MGP promoter constructs containing 59
as well as internal deletions. We identified a novel NRE
located between nucleotides 2168 and 2132 bp. Activity of a
mutant promoter, lacking this region, is no longer repressed by
ligand-activated RARyRXR. DNA binding studies, per-
formed with bacterially expressed RAR and RXR, reveal the
formation of a specific RARyRXRyNRE complex. In addi-
tion, EMSAs performed with extracts from RA-treated cells
demonstrate the formation of a specific NREyprotein com-
plex. The NREyprotein complex is recognized by an a-RXR
antibody, clearly demonstrating that RXR, present in NRK52E
cells, binds to the NRE. Importantly, the NRE shows no
sequence homology to previously identified negative RA
response elements like the previously reported NRE in the rat
oxytocin promoter (22).
Mechanistically, negative gene regulation mediated by nuclear
receptors can be achieved by the competition between receptors
and positive transacting factors for common or overlapping
binding sites (9, 10). Alternatively, repression might also occur
through direct protein–protein interactions between receptors
FIG. 4. (A) RARyRXR binds to the hMGP promoter in vitro. EMSAs were performed by incubating a 32P-labeled oligonucleotide containing
the NRE sequence (2168 to 2132 bp) with purified recombinant GST-RAR (lane 2) and GST-RXR (lane 3) or both proteins (lane 4). The
RARyRXR heterodimer shift is specifically supershifted by an a-RAR antibody (lane 5) as well as by an a-RXR antibody (lane 6). Competition
experiments were performed by using the indicated competitors in a 50- or 200-fold molar excess. The retarded receptoryDNA complex is competed
by the unlabeled DR5 oligonucleotide (lanes 7 and 8), DR2 oligonucleotide (lanes 9 and 10), and NRE oligonucleotide (lanes 11 and 12). Bacterially
expressed GST-protein was also added as a control (lane 1). (B) Purified GST-RARyGST-RXR were incubated with a 32P-labeled oligonucleotide
containing the NRE sequence (2168 to2132 bp). The RARyRXR shift is specifically competed by a 200-fold molar excess of NRE oligonucleotide
(lanes 2 and 3). Oligonucleotide MT1 (2157 to 2132 bp) competes only very little (lanes 4 and 5), whereas oligonucleotide MT2 (2154 to 2137
bp) fails to compete (lanes 6 and 7). (C) RXR binds to the hMGP promoter in vivo. Samples (2 ml) of whole cell extracts prepared from RA-treated
NRK52E cells were incubated with the 32P-labeled NRE probe. The DNAyprotein complexes are specifically competed by a 100-fold molar excess
of NRE oligonucleotide (lane 3). In contrast, oligonucleotide DR5 competes only complex II (lane 4). To establish the composition of the
DNAyprotein complexes, the EMSAs were challenged with a-RXR (lane 6) or unrelated a-Flag antibodies (lane 5).
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and transcriptional activators. Such protein–protein interactions
might interfere with the DNA binding andyor transactivation
properties of the transcriptional activator (14). In addition, recent
reports describe that the cofactors CBPyp300 directly interact
with the ligand binding domain of multiple nuclear receptors.
CBPyp300 might serve as a common cofactor for many tran-
scription factors and competition for limiting amounts of CBPy
p300 might account for many of the inhibitory actions of RAR
and glucocorticoid receptor on AP-1 activity (11, 12).
To better understand the mechanism of RAR-mediated
MGP gene repression, deletion mapping studies were used to
identify domains in the RAR responsible for repression.
Nuclear receptor function depends on a conserved motif
within the C terminus, referred to as the AF-2 domain. Several
lines of evidence indicate that nuclear receptors such as RAR
or TR interact with certain cofactors in an AF-2- and ligand-
dependent fashion. These interactions release the binding of
corepressors like N-CoRySMRT and allow the receptors to be
transcriptional activators (23, 24). Accordingly, the deletion
mutant RAR403*, in which the AF-2 core is lacking, functions
as an RA-independent, constitutive repressor. In clear con-
trast, our data show that RAR403* is unable to repress hMGP
promoter activity. Furthermore, overexpression of SMRT
does not influence RA-mediated MGP repression (data not
shown). In addition, the DBD deletion mutant RARDDBD,
which cannot bind DNA, fails to repress hMGP promoter
activity. In summary, our results indicated that the DBD and
the AF-2 function of RAR are necessary for repression.
Interestingly, the NRE in the hMGP promoter contains a
CCAAT box. To test for mutual binding of RARyRXR
heterodimers or CCAAT-binding factors such as cyEBPb, we
tested the ability of RARyRXR and cyEBPb to bind the NRE.
DNA binding studies reveal that RARyRXR and cyEBPb can
recognize this common regulatory sequence in the hMGP
promoter. Additionally, our data indicate that RARyRXR
does not interact with cyEBPb bound to the NRE. Indeed,
GST-pulldown and mammalian two-hybrid assays reveal no
heteromeric protein–protein interactions between cyEBPb
and RARyRXR (data not shown). These results suggest that
RA-mediated repression of the hMGP gene is dependent on
the binding of RARyRXR to overlapping cyEBPb binding
sites. Consequently, overexpression of cyEBPb can overcome
RA-mediated repression of the hMGP promoter.
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FIG. 5. (A) RARyRXR and cyEBPb recognize an overlapping
binding site. The EMSAs were performed by using the 32P-labeled
NRE oligonucleotide and purified recombinant GST-RAR, GST-
RXR, GST-cyEBPb, and GST. To determine binding of these proteins
to the NRE sequence, equal amounts of GST (lane 1), GST-RAR and
GST-RXR (lanes 2 and 9), GST-cyEBPb (lanes 3 and 8), or a
combination of GST-RARyGST-RXR and GST-cyEBPb (lanes 4–7)
were incubated with the probe. To establish the composition of the
different complexes, the EMSAs were challenged with a-RXR (lane
6) or a-cyEBPb antibodies (lanes 7 and 8). The RARyRXRyNRE
complex is denoted C1, the cyEBPbyNRE complexes are denoted C2
and C3. (B) cyEBPb is able to abrogate RARyRXR-mediated re-
pression. The reporter plasmid -168LUC was cotransfected in
NRK52E cells together with constant amounts of plasmids expressing
RAR, RXR, and various amounts of expression vector encoding
cyEBPb. The cells were either untreated (open bars) or treated with
1026 M all-trans RA (hatched bars). Numbers indicate the amount of
cotransfected plasmid DNA in micrograms.
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